MIRA Pharmaceuticals Presents New Preclinical Data For Ketamir-2 At Prestigious 18th Annual Pain Therapeutics Summit

MIRA Pharmaceuticals, Inc., a development-stage pharmaceutical company focused on the discovery and development of new treatments for neurological and neuropsychiatric disorders, announced that new preclinical data related to its lead product, Ketamir-2, will be featured at the 18th Annual Pain Therapeutics Summit in Boston, MA, on 29th October. The presentation, "Selective NMDA Receptor Modulation: The Superior Efficacy of Ketamir-2 in Neuropathic Pain Treatment," will highlight the significant finding that Ketamir-2 completely reverses neuropathic pain in preclinical models.

The Summit provides a premier forum through which researchers, clinicians, and industrial experts can discuss the most innovative approaches to pain management. MIRA's involvement demonstrates its commitment to significant unmet medical needs in the area of neuropathic pain, which is often chronic and debilitating and for which there are alternatives for inadequate.

Neuropathic pain, resulting from nerve damage or dysfunction, presents a significant challenge in pain management due to the limited effectiveness and side effects of existing treatments. However, Ketamir-2, a novel oral analogue of ketamine, selectively targets the PCP site of the NMDA receptor, providing improved efficacy with fewer side effects than traditional ketamine.

In preclinical trials utilizing the Chung model for neuropathic pain, oral administration of Ketamir-2 outperformed ketamine, resulting in a complete reversal of pain responses, effectively restoring normal function.

Results speak for the revolutionary nature of the new therapy in the case of Ketamir-2, and relief from pain is achieved with a much smaller risk of adverse effects.

Chief Scientific Advisor of MIRA, Dr. Itzchak Angel, said in a statement, "The data from our preclinical studies on Ketamir-2 are groundbreaking. Achieving a full normalization of response to neuropathic pain in our model suggests that Ketamir-2 has the potential to significantly outperform existing treatments, offering a new level of relief for patients suffering from chronic neuropathic pain. We are excited to present these findings to the broader scientific community and continue progressing toward clinical trials." 

MIRA will continue with the advancement of Ketamir-2 in additional preclinical work and expects to publish its results in peer-reviewed journals. The firm will also file for an IND with the U.S. by December 2024. FDA submissions are planned to demonstrate clinical efficacy in humans by 2025. To accomplish this, MIRA engineered Phase I and II studies that would highlight the clinical utility of Ketamir-2 for neuropathic pain and potentially other neurodegenerative disorders. This strategy speaks to the company's current approach to accelerating its journey to the clinic, providing early substantial data, and facilitating necessary decisions as quickly as possible to expedite patients' access to these innovative treatments eventually.

"We are thrilled to present our preclinical data at the 18th Annual Pain Therapeutics Summit. Ketamir-2 represents a significant advancement in the treatment of neuropathic pain, and we are committed to accelerating its development to bring this novel therapy to patients in need," said Erez Aminov, CEO of MIRA.